PHILADELPHIA, Dec. 4, 2017 /PRNewswire/ -- Aevi Genomic
Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today the
appointment of Matthew D. Bayley,
MD, MBA to its Board of Directors.
"We are excited to welcome Matt to our Board of Directors during
this important time for the Company," said Mike Cola, CEO of Aevi Genomic Medicine. "He has
played a key role in advancing the strategic direction at
Children's Hospital of Philadelphia, and his industry experiences and
keen business insights will bring a valuable perspective to the
Company."
Dr. Bayley currently serves as a Senior Vice President and Chief
Strategy Officer at the Children's Hospital of Philadelphia (CHOP) where he leads strategic
planning and business development efforts and supports the CEO in
developing the strategy of advancing CHOP's mission. Prior to
joining CHOP, he was a Partner at McKinsey & Company, a global
management consulting firm, where his work focused on strategy,
operations, and organizational topics in the healthcare
field. Dr. Bayley graduated from the University of Virginia's McIntire School of Commerce, and went on to
receive his M.D. from the University of
Pennsylvania School of Medicine and an M.B.A. from the
Wharton School.
About Aevi Genomic Medicine, Inc.
Aevi Genomic Medicine, Inc. is dedicated to unlocking the
potential of genomic medicine to translate genetic discoveries into
novel therapies. Driven by a commitment to patients with pediatric
onset life-altering diseases, the company's research and
development efforts leverages an internal genomics platform and an
ongoing collaboration with the Center for Applied Genomics (CAG) at
The Children's Hospital of Philadelphia (CHOP).
Forward-looking Statements
This release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934 and as that term
is defined in the Private Securities Litigation Reform Act of 1995,
which include all statements other than statements of historical
fact, including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend,"
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
CONTACT:
Aevi Genomic Medicine, Inc.
Brian Piper
Brian.Piper@aevigenomics.com
Westwicke Partners
Chris Brinzey
339-970-2843
Chris.brinzey@westwicke.com
MEDIA INQUIRIES:
FTI Consulting
Irma Gomez-Dib
+1-212-850-5761
+1-415-706-9155
irma.gomez-dib@fticonsulting.com
View original
content:http://www.prnewswire.com/news-releases/aevi-genomic-medicine-announces-new-appointment-to-its-board-of-directors-300566085.html
SOURCE Aevi Genomic Medicine, Inc.